The TCEB2 antibody targets the Transcription Elongation Factor B (TCEB) subunit 2. a protein also known as Elongin B. TCEB2 is a key component of the Elongin complex, which plays a critical role in transcriptional regulation and protein ubiquitination. It forms a heterotrimeric complex with Elongin A (TCEB1) and Elongin C (TCEB3) to enhance RNA polymerase II transcriptional elongation. Additionally, TCEB2 interacts with the von Hippel-Lindau (VHL) tumor suppressor protein as part of the E3 ubiquitin ligase complex, facilitating hypoxia-inducible factor (HIF) degradation under normoxic conditions. Dysregulation of TCEB2 has been implicated in cancers, particularly renal cell carcinomas, where mutations in VHL or related pathways disrupt HIF regulation. Antibodies against TCEB2 are widely used in research to study its expression, localization, and interactions in cellular processes, including hypoxia response, DNA repair, and tumorigenesis. They are essential tools in techniques like Western blotting, immunoprecipitation, and immunohistochemistry. Recent studies also explore TCEB2’s role in modulating cullin-RING ligase (CRL) complexes, highlighting its broader impact on proteostasis and cellular signaling. As a conserved protein across eukaryotes, TCEB2 antibodies contribute to both basic molecular research and clinical investigations targeting cancer mechanisms.